Rhythm Pharmaceuticals Inc (RYTM)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month...

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

-- IMCIVREE® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient...

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z...

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form ARS - Annual Report to Security Holders